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Baseline patient features 
 
Best survivors All ATAP 
 
Sex N % N % 
 
Male 8 27 % 167 42 % 
 
Female 22 73 % 123 58 % 
 Age 
 Median 58 
 
58 
 Mean 54 
 
56 




WHO performance status N % N % 
 
0 8 27 % 29 10 % 
 
1 18 60 % 129 44 % 
 
2 4 13 % 114 39 % 
 









Cancer type N % N % 
 
Breast 4 13 % 35 12 % 
 
Cervical 0 0 % 6 2 % 
 
Colorectal 1 3 % 49 17 % 
 
Hepato/cholangio 1 3 % 8 3 % 
 
Head and neck/Thyroid 3 10 % 12 4 % 
 
Gastric 0 0 % 11 4 % 
 
Lung 4 13 % 22 8 % 
 
Melanoma 1 3 % 15 5 % 
 
Meso/sarcoma 6 20 % 36 12 % 
 
Neuroend/-blast 1 3 % 5 2 % 
 
Ovarian 7 23 % 39 13 % 
 
Pancreatic 0 0 % 30 10 % 
 
Prostate 2 7 % 14 5 % 
 
Urinary tract 0 0 % 8 3 % 
 Previous treatments N % N % 
 
Surgery 22 70 % 195 67 % 
 
Radiotherapy 14 47 % 142 49 % 
 
Chemotherapy 29 93 % 287 99 % 
 
Median chemo regimens 3 
 
4 
 Mean chemo regimens 4,1 
 
4,2 
















Patient treatments, responses and survival 
 
Best survivors All ATAP 
 
30 100 % 290 100 % 
 Viral treatments N % N % 
  1-3 15 50 % 240 83 % 
  4-8 10 33 % 43 15 % 





 median 4 
 
3 
       
Serial treatment * 7 23 % 154 53 % 
Low-dose cyclophoshamide ** 26 87 % 223 77 % 
 
First imaging response 
    CR/CMR 7 23 % 9 3 % 
PR/PMD 3 10 % 5 2 % 
 
MR/MMR 3 10 % 16 6 % 
 
SD/SMD 11 37 % 40 14 % 
 
PD/PMD 5 17 % 106 37 % 
 
NA 1 3 % 114 39 % 
      
 
Best imaging response 
CR/CMR 7 23 % 9 3 % 
PR/PMD 3 10 % 5 2 % 
 
MR/MMR 4 13 % 18 6 % 
 
SD/SMD 12 40 % 44 15 % 
 
PD/PMD 3 10 % 100 34 % 
 
NA 1 3 % 114 39 % 
      
 
Best marker response***  
CR 1 3 % 3 1 % 
R 0 0 % 12 4 % 
 
MR 5 17 % 26 9 % 
 
SD 0 0 % 24 8 % 
 
PD 5 17 % 65 22 % 
 
NA 19 63 % 160 55 % 
      
 
OS mean 1186 265 




           
*Patient received at least one “serial treatment” (3 treatments during a 10 week 
period , see patients and methods) 
** low dose cyclophosphamide  was used to reduce regulatory T-cells (see patients 
and methods) 
*** tumor marker molecules measured from blood to evaluate treatment effects 
CR/CMR=Complete response/complete metabolite response 













MR/MMR=Minor response/minor metabolite response, 12-29% reduction 
SD/SMD=Stable disease/stable metabolite disease 
PD/PMR=Progressive disease/Progressive metabolite disease >30% increase 
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The first FDA and EMA approved oncolytic virus has been available since 2015. However, there are 
no markers available that would predict benefit for the individual patient. During 2007-2012 we 
treated 290 patients with advanced chemotherapy refractory cancers, using 10 different oncolytic 
adenoviruses. Treatments were given in a FIMEA regulated individualized patient treatment 
program (the Advanced Therapy Access Program ATAP), which required long term follow-up of 
patients, which is presented here. Focusing on the longest surviving patients, some key clinical and 
biological features are presented as “oncograms”.  Some key attributes that could be captured in 
the oncogram are suggested to predict treatment response and survival after oncolytic adenovirus 
treatment. The oncogram includes immunological laboratory parameters assessed in peripheral 
blood (leukocytes, neutrophil-to-lymphocyte ratio, IL-8, HMGB1, anti-viral neutralizing antibody 
status), features of the patient (gender, performance status), tumor features (histological tumor 
type, tumor load, region of metastases) and oncolytic virus specific features (arming of the virus). 
The retrospective approach used here facilitates verification in a prospective controlled trial 
setting. To our knowledge the oncogram is the first holistic attempt to identify the patients most 
likely to benefit from adenoviral oncolytic virotherapy.         
Introduction 
Cancer immunotherapy has provided several exciting breakthroughs during the past few years. 















several new treatments able to generate durable responses. For most types of advanced cancers 
this is a new situation since surgery, chemotherapy, radiation, kinase inhibitors and hormonal 
therapies are usually not curative when the patient has metastatic disease.  
Checkpoint inhibitors have shown efficacy in a variety of tumors and approval is likely for several 
new indications in addition to the half dozen already approved
1-3
. Also different cell based 
therapies have shown promising results over the past few decades and two products have been 
approved
4, 5
. Oncolytic viruses have progressed steadily in trials and the first FDA and EMA 
approvals were granted in 2015
6
, with further viruses likely to be approved later. Interleukin-2 and 
interferon alpha have been used with variable enthusiasm for a few decades and some patients 
show durable long term responses
7
. Probably the most routine use of immunotherapy has been 
the Bacillus Calmette-Guérin (BCG) for superficial bladder cancer
8
. With all this excitement it can 
be forgotten that each of these immunotherapies only work in a subgroup of patients. For 
example, when used as single agents, FDA approved checkpoint inhibitors only provide responses 
in 10-50% of patients, depending on tumor type
1-3
.  
It would be of key relevance to identify the patients most likely to benefit from each approach. 
Human suffering could be reduced and monetary resources saved if patients would be directly 
treated with the most effective drug or combination, especially if long term efficacy results.  
Emerging evidence suggests that the immune status of tumors varies
9
. Tumors can be grouped 
roughly into “hot”, “immunologically excluded” and “cold” tumors
3, 10, 11
. The latter two types are 
often combined, resulting in just two groups: “hot” and “cold”. A typical “hot” tumor has a high 
mutational load, in particular featuring neoantigens and subsequently ample CD8+ T-cells 
recognizing said mutations. In theory such T-cells should result in tumor destruction but obviously 















results in an immunosuppressive counter-reaction, it is logical that “hot” tumors typically display 
programmed death ligand-1 (PD-L1) expression, which is one of the factors associated with T-cell 
anergy and survival of tumor cells. In such “hot” tumors checkpoint inhibitors that block the PD-
1/PD-L1 interaction are known to result in high response rates
12
.  
These developments underline the utility of understanding the underlying molecular mechanisms 
for optimal patient selection. This is employed in lung cancer for example, where some anti-PD-1 
drugs are only approved for PD-L1 positive tumors
3
. 
In “cold” tumors the mutational load of the tumor is generally lower and the tumor tissue lacks 
cells of the adaptive immune system which may indicate that the immune system has been unable 
to recognize the tumor. Thus also T-cell activating checkpoint inhibitors have generally poor 
efficacy
13
. Emerging data suggest that agents such as oncolytic viruses are able to cause 
inflammation, tumor cell destruction and activation of the immune system against these tumors
10, 
11, 13-16
. In essence, oncolytic viruses may be able to convert “cold” into “hot” tumor, making them 
uniquely attractive in this subgroup of patients
11, 17
.  
During 2007-2012 290 patients were treated with oncolytic adenoviruses in an Advanced Therapy 
Access Program (ATAP)
6
. Altogether ten different viruses were used in 821 individualized 
treatments
18-23
. The adenoviruses used were engineered so that they could replicate only in tumor 
cells. Most of these viruses were based on serotype 5, but some had the fiber knob of serotype 
3
11, 19
 (to enhance tumor transduction) and one virus was fully serotype 3 based
24, 25
. Adenovirus 
infection per se induces immunogenic cell death
26
 but to further activate the immune system 




. In many 















benefit from the treatments. Using retrospective analysis we have previously been able to 
recognize several factors that seemed to correlate with good responses and survival
14, 18, 25, 27-29
.  
Here we have attempted to analyze and refine the clinical and biological information gleaned from 
the patient treatment program. Inspired by the cancer immunogram published by Blank et al 
9
, we 
developed an oncolytic virus specific “oncogram” to present the key predictive and prognostic 
factors in a compact and visual way using actual patients as examples. We have not seen a similar 
patient-by-patient approach for oncolytic viruses or other immunotherapeutics – the model 
published by Blank et al was largely theoretical 
9
.  We believe the oncogram is a practically usable 
tool for identifying cancer patients most likely to benefit from oncolytic adenovirus treatment, and 
could apply also to other viruses although this remains to be studied.  
Patients and Methods 
In the advanced therapy access program (ATAP) patients were treated in an individualized patient 
by patient basis - not according to a preplanned study protocol. Different oncolytic adenoviruses 
were used to treat various types of solid tumors. Treatments are described in more detail 
elsewhere 
6, 11, 24, 25
 
14, 18, 27
. Treatments took place in Docrates Hospital, Helsinki, Finland. In most 
cases virus was injected directly in to the tumor by a radiologist, but also intravenous and 
intraperitoneal treatment was utilized. As described previously 
6, 11, 24, 25
 
14, 18, 27
, treatments were 
well tolerated. In general, tumor pain, flu-like symptoms, fever and fatigue resulted from 
treatment.  
In the present evaluation data from the thirty patients with the longest survival was included. 
These patients were compared to all patients in the ATAP and to the worst surviving patients. The 















of patients per cancer type were taken as controls; for example the four best surviving breast 
cancer patients were compared to the four breast cancer patients who survived the least. 
Oncograms include eleven predictive or prognostic variables with patients treated with oncolytic 
immunotherapy 
14
. Individual patient oncograms are designed so that good variables (recorded 
before first oncolytic virus treatment) are present at the outer ring, these include: 1) female 
gender 2) WHO 0-1 3) cancers other than melanoma, colorectal, pancreatic, hepatocellular or 
cholangio carcinoma 4) low tumor load 5) peritoneal metastases without liver metastases 6) low 
neutrophil to lymphocyte ratio (low neutrophils and/or high lymphocytes) 7) low leucocyte value 
8) low IL-8 9) low HMGB1
27
 10) First treatments with GM-CSF or CD40L armed virus 11) no anti-
viral neutralizing antibodies
14
. Inner ring values include poor prognostic variables. Variables that 
were not available are marked in the middle ring and the label was removed from the oncogram. 
Patients that had liver metastases (poor prognostic marker)
14
 and peritoneal metastasis (good 
prognostic marker) or no metastasis were also marked at the middle ring. In figure 4 a) where 
oncogram averages are presented by tumor type we took into account also values that were not 
available by using a value of 0.5 while in panel b) the not-available values were left out. This was 
due to low number of variables present in panel a) and thus single available variables would have 
distorted the average oncogram considerably. Especially laboratory analysis were not available for 
some patients before treatments. In statistical analyses the not-available values were naturally not 
taken into account.   
The retrospective analysis of these patients was approved by the HUS Operative Ethics Committee 
and the treatments were in accordance with the Declaration of Helsinki. Survival information was 















Statistical analyses were performed using Student’s t-test and Fisher´s exact test in the case of 
figure 4 (as suggested by a statistican). Two-tailed test was used and p values of <0.05 were 
considered significant.  
Serial oncolytic viral treatment where three injections of virus during a ten week period was given 
to part of the patients before evaluating treatment efficacy 
30
. Low dose cyclophosphamide was 




To date 5-10 year follow up of ATAP
6
 patients is possible. All patients had advanced solid tumors, 
and had gone through routine evidence-based treatments before entering ATAP (Supplementary 
Table 1). Most patients were heavily pre-treated with a median of 4 prior lines of medical 
therapies (Table 1). In this study we focused on the thirty longest surviving patients, their tumor 
type matched controls (with short survival) and compared them with the overall ATAP population 
(Figure 1). The median survival of these long term survivors (N=30) was 921 days, while the 
median survival in the general ATAP population (N=290) was 132 days and the worst surviving 
controls (N=26) had a survival of only 51 days underlining the advanced disease status of typical 
ATAP patients. 
Slightly more patients participating in ATAP were female (58%, Table 1). In contrast, 73% of the 
long term survivors were women (p=0.001). The general performance status of the long term 
survivors was also better (87% WHO/ECOG 0-1) compared to all ATAP patients (54% WHO/ECOG 
0-1, p<0.001). Ovarian cancer, lung cancer, mesothelioma and sarcoma patients seemed to be 
common in the best survivors while only 1 of the 79 patients with colorectal or pancreatic cancer 
patients contributed to this group. Age and number of previous treatments were similar between 
















Long term survivors received a higher number of viral treatments (50% had received 4-18 
treatments, Table 2) compared to the overall ATAP population (19% received 4-18 treatments, 
p=0.002). This doesn’t necessarily indicate causality since it is logical that if the patient was alive 
they might want to continue therapy. Of the best survivors 23% presented a complete response or 
a continuing complete response evaluated by computed tomography (CT) or by positron emission 
tomography–computed tomography (PET-CT) while in all ATAP patients this was seen only in 3% 
(p<0.001). Similar findings were recorded with patients who had evaluable tumor markers before 
virus treatments. Over half (6 out of 11) of the evaluable best survivors showed a marker response 
compared to less than one third (41 out of 130) of all evaluable ATAP patients (p=0.12). The first 
imaging response was typically also the best response. In ATAP overall, 53% of patients received a 
more intensive ”serial treatment” (three treatments within 10 weeks)
30
. Interestingly, only 23% of 
the best survivors had received this (p=0.002). Again, there might not be causality. Instead, it 
could be that if the first injection immediately shrinked tumors or the tumors were 
small/technically demanding to inject, it might have been difficult to continue with intratumoral 
injections.  
Oncograms of the best surviving 30 patients are shown in figure 2 and the oncograms of the worst 
surviving control patients are shown in supplementary figure 1. Each oncogram consists of 11 
variables that have been considered important in previous publications from this ATAP cohort 
14, 
18, 25, 27-29
. These significant factors that seem to affect survival of the patients are summarized in 
supplementary table 2. Favorable variants (see patients and methods for details) are placed on the 
outer ring and non-favorable variants on the inner ring, similarly as in the previously published 
immunogram
9















middle ring. In the case of metastases, liver metastases have been reported to indicate poor 
prognosis and were placed on the inner ring while peritoneal metastases have been reported 
favorable
14
 and were thus marked on the outer ring. If metastases were in other organs, there 
were no metastases or metastases were both peritoneal and hepatic, this was marked on the 
middle ring.  
With this system where favorable factors are always on the outer ring and unfavorable on the 
inner ring, oncograms with a large surface area indicate patients with many favorable factors in 
the context of oncolytic adenovirus treatments. In contrast, oncograms with small surface area 
propose the opposite.  
In the best surviving thirty patients there were seven ovarian cancer patients (patient code 
starting with O, figure 2). If we compare these to the worst surviving ovarian cancer patients 
(Supplementary Fig 1) even the patient by patient oncograms appear different. This exemplifies 
how the oncogram can be used for clinical decision-making; perhaps ovarian cancer patients with 
a small area oncogram should have received another type of therapy. Obviously, this remains to 
be prospectively studied. The oncogram can also be used to generate biological hypotheses. For 
example, it was interesting to note that many of the long surviving ovarian cancer patients had 
peritoneal metastasis while the short surviving patients seemed to have unfavorable neutrophil to 
lymphocyte ratio. Perhaps partially explaining this, it has been speculated previously that the 
peritoneal cavity can be considered an immunological organ
30, 32
, while the neutrophil to 
lymphocyte ratio seems to indicate immune competence
14
.  
Similarly the oncograms of the best surviving breast cancer patients (patient code starting with R, 















was not as evident with lung cancer (n=4, patient code starting with K) or sarcoma (n=4, patient 
code starting with S).  
Patient by patient viral treatments, imaging responses and survival are shown in figure 3. Patients 
are grouped by tumor type. The individualized patient treatments and variable responses can be 
noted from this figure. With some patients (C332, O198, R218) imaging seemed to predict 
prognosis as these patients are still alive. On the other hand patient I98 responded only partly and 
patient S119 showed continuously stable disease in imaging, but both of these patients are still 
alive. Interestingly some patients show progressive disease after virus treatments (P251, S354, 
O205, R255) but still survived a relatively long time (>2 years). “False negatives” (lack of response 
in imaging) might be due to inflammatory pseudoprogression caused by the immune response 
generated by the virus at the tumor
32
. Although pseudoprogression is now well appreciated in the 
context of immunotherapy, this was not the case 10 years ago when ATAP patients were being 
treated
33
. In ATAP patients were monitored with traditional Response Evaluation Criteria in Solid 
Tumours (RECIST) or PET Response Criteria developed for monitoring traditional chemotherapy 
responses
32
. Also, it was not appreciated that immunotherapy can take a long time to work. In 
ATAP, patients typically stopped receiving further treatment if the first imaging (after a median of 
63 days)
32
 was not indicative of disease control. New guidelines for monitoring 
immunotherapeutics have recently been introduced
34
.   
To take full advantage of visual presentation, mean (average) oncograms of the best surviving 
patients were overlaid with those of the short-surviving controls (Figure 4). Sarcoma, ovarian, 
breast and lung cancer patients are shown by tumor type since more than three patients were 
among the “top 30” (Figure 4a).  Interestingly, ovarian (n=7) and breast (n=4) cancer oncograms 















patients while this was not as evident for lung cancer (n=4) or sarcoma (n=4) oncograms (p=0.517 
and p=0.051 respectively). The averages of the best (n=30) and worst (n=26) surviving patients’ 
oncograms were overlaid and an area size difference was detected (p=0.000002, Figure 4b).  
Despite small patient number we also looked into individual factors. With ovarian, breast and “all 
cancers” the difference in performance status (WHO) was significant (p=0.002, p=0.03, p<0.001 
respectively). With ovarian cancer, arming of the virus was a significant component (p=0.03) while 
the female gender (p=0.03) showed significance in lung cancer. In addition to performance status, 
neutrophil to lymphocyte ratio (NLR) and neutralizing antibodies (NAb) against the treatment virus 
showed significant differences (p=0.001 and p=0.04 respectively) in the “all cancers” group. The 
leukocyte difference here was borderline (p=0.054).   
    
Discussion 
The oncogram approach was developed by combining individual factors that have been suggested 
to predict good survival following oncolytic virus treatment
14, 25, 28
. The manner of presentation 
was inspired by the immunogram approach where seven parameters were described
9
. The main 
difference between the oncogram and the immunogram is that the former is being proposed as a 
patient-by-patient practical decision-making tool for patients being considered for oncolytic 
adenovirus treatment while the latter is a more theoretical concept that might broadly apply to 
immunotherapy but has not been applied to patients yet. Important practical aspects of the 
oncogram include that all of the variables can be measured at baseline, and without the need for 
biopsies or expensive techniques. Of note, the oncogram is a patient-specific tool which considers 















Many similarities can be found between the parameters of the immunogram and the factors we 
found significant in our ATAP series, which were then included in the oncogram. Both recognize 
that blood lymphocytes and other immunological soluble markers play a role. In the immunogram, 
factors such as lymphocytes, Il-6, CRP, LDH are suggested based on theoretical considerations 
while in oncolytic virus treated patients leukocytes, neutrophil-lymphocyte ratio, IL-8 and HMGB1 
were found significant following actual measurements in patients
14
. Clinical factors such as 
gender, performance score, tumor type or metastatic burden are not taken into account in the 
immunogram while tumor load and site of metastases was found relevant in oncolytic virus 
treated patients.  
Five out of the seven variables proposed in the immunogram would need tumor biopsy which is 
not always practical. None of the variables present in the oncogram require biopsy and all can be 
measured at baseline with inexpensive widely available techniques. Also, even if biopsies were 
available, there are no standardized ways for measuring mutational load, interferon gamma 
sensitivity or glucose utilization (immunogram parameters). Even measurement of intratumoral T-
cells and PD-L1 currently lack standardization despite the importance of these factors in predicting 
efficacy of PD-1/PD-L1 inhibitors 
1-3, 12, 13
.  
Some of the factors captured in the oncogram are intuitive. For example, patients with good 
performance status (WHO) at baseline were overrepresented in the thirty long term survivors. 
Perhaps the immune system of such patients is better capable of mounting an anti-tumor immune 
response. However, good performance score patients might have lived longer even without any 
treatment. When ATAP was started in 2007 oncolytic viruses were thought to act mostly through 
oncolysis, which might be expected to occur rapidly, creating rationale for treatment of even late 















induction of the anti-tumor immune response, and this can take time
6
. For example, in the 
oncolytic herpes T-Vec Phase 3 trial, almost half (23 out of 48) of the durable responses showed 
progression prior to response defined as the appearance of a new lesion or >25% increase in total 
tumor area. Many responses were seen only after several months or even after a year
35
. The same 
has been seen for anti-PD1 drugs 
1-3, 12, 13
. Similarly pointing at the importance of the immune 





). Nevertheless, oncolysis and tumor 
transduction could play a role as suggested by the finding that the longest survivors had less 
neutralizing antibodies against the treatment virus. 
The immunogram authors proposed that the approach could help to choose the right 
immunological treatment between PD-1 blockade, combined PD-1 and CTLA-4 blockade or T-cell 
treatment. We believe oncolytic viruses could be added to the treatment arsenal as these are 
proposed to be potent in the “cold” non-inflamed tumor environment
36
 where checkpoint 
inhibitors and other immunotherapeutics appear to have poor efficacy. We and others have 
suggested that oncolytic viruses work best in tumors with a low amount of immune cells
10, 11, 13-16
. 
In contrast, checkpoint inhibition works best when the tumor features neoantigens, resulting in 
tumor infiltrating lymphocytes and (probably reactive) PD-L1 expression 
1-3, 12, 13
. Logically, 
excellent preliminary results have already been seen when oncolytic virus treatment was 
combined with checkpoint inhibition. With this combination a 62% response rate and a 33% 
complete response rate in advanced melanoma was noted
13
. However, although the combination 
appears very well tolerated, for some patients it might represent overtreatment. The oncogram, 
with or without the immunogram, could help identify patients for whom single or combined 















The oncogram presented here is designed to evaluate patients most suitable for oncolytic 
immunotherapy. If tumor biopsies were available it would be possible to systematically analyze 
many immunological factors as has been done with the Immunoscore for example
37
. Although the 
oncogram as presented here does not require biopsies, having tissue might improve the decision-
making process further. In some individual ATAP patients biopsies before and after treatment 
were available. Their analyses suggested that tumors with a low amount of immune cells pre-
treatment respond to oncolytic virus treatment in conjunction with recruitment of immune cells to 
the tumor during treatment. In contrast, tumors with an extensive immune infiltrate pre-
treatment did not respond and little difference was observed in the post-treatment biopsy
11, 36
. 
This is in line with our proposal: Patients with large area oncograms and cold tumors (low amount 
of immune cells, few neoantigens, low PD-L1) could be treated with oncolytic viruses while 
patients with small oncograms, hot tumors with ample immune cells and high PD-L1 staining could 
be considered primarily for checkpoint therapies or checkpoint combinations. Intermediate and 
mixed cases, which probably includes most patients in a real-life situation, could be treated with 
the oncolytic virus + checkpoint inhibitor combination. Obviously, all of these notions require 
prospective evaluation in trials.  
A key attraction of the oncogram is the ease of evaluating the 11 variables. Some are fairly obvious 
(gender, tumor type), while many others are already routinely evaluated (leukocytes, NLR, tumor 
load, location of metastases, performance score). The remainder (antibodies, HMGB1, IL-8) 
require a simple blood test followed by an inexpensive assay. In a real world situation it is 
unrealistic to expect that extensive tumor materials, such as needed for multiple complex 
analyses, would be available from patients undergoing routine treatment, especially when 
considering tumor types such as pancreatic cancer or glioma, or tumor recurring at distant sites 















such cases. It is also increasingly clear that the immunological and mutational status of different 
metastases vary significantly, and thus a single biopsy from one tumor or metastasis might not 
give a comprehensive tumor-immunological view of the patient
38
. In addition to or as a 
replacement to biopsies it is conceivable that immunological evaluation of tumors can also be 
performed by imaging. This seems especially evident with magnetic imaging or magnetic 
spectroscopy
28
. Interesting novel approaches which could eventually complement the oncogram 
include non-invasive PET based T-cell imaging or PD-L1 imaging
39-41
.  
In conclusion, we believe that in the future cancer treatment will become more individualized, and 
this applies also to immunotherapy. This means that more factors, including multiple 
immunological markers, should be taken into account for optimizing drug selection and 
sequencing of treatments. The oncogram presented here constitutes a patient-data-driven 
hypothesis for choosing suitable patients for oncolytic therapy. More elaborate immunological 
analysis of tumor biopsies, blood, the lymphatic system or immunological imaging might further 
help to choose the optimal treatment for each patient. Clinical trials are needed to validate these 
preliminary findings.         
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Fig 1 Survival of all ATAP patients (2), including the subgroups of the best (1) and worst (3) 
survivors. 
Fig 2 Oncograms of the best surviving patients. Values at the outer rim indicate good prognostic or 
predictive variables while values at the inner rim indicate the opposite. Data that was not available 
is indicated with data points in between and the outer rim does not have labeling. Good 
prognostic variables, as recorded before first oncolytic virus treatment, include: 1) female gender 
2) WHO 0-1 3) cancers other than melanoma, colorectal, pancreatic, hepatocellular or cholangio 4) 
low tumor load 5) peritoneal metastases without liver metastases 6) low neutrophil to lymphocyte 
ratio 7) low leucocyte value 8) low IL-8 9) low HMGB1 10) First treatments with GM-CSF or CD40L 
armed virus 11) no anti-viral neutralizing antibodies.  
Fig 3 Swimmers plot: patient by patient oncolytic virus treatments, responses and survival.  
Fig 4 a) Average oncograms by tumor type of the best surviving patients (when more than three 
patients per group were present) compared to the worst surviving controls. b) Average oncograms 
of all best surviving patients (N=30) compared to the worst surviving controls (N=26). * P<0.05 ** 
P<0.01 *** P<0.001 Fisher´s exact test. When all variables (best survivors N=243, worst survivors 
N=174) were compared P=0.000002.  
Table 1 Patient features before first oncolytic virus treatment 
Table 2 Patient treatments, responses and survival 
Suppl Fig 1 Oncograms of the worst surviving patients. Values at the outer rim indicate good 















was not available is indicated with data points in between and the outer rim does not have 
labeling.  
Suppl Table 1 Individual patient features and prior treatments  
Supplementary table 2 
Significant data for Overall survival/Cancer mortality Ref 
Variable 
(suggesting good 
OS, outer ring in 
the oncograms) 
P value HR (95% CI)  












0.108 (0.048–0.244) WHO 0 









































0.065 (0.021 RR) no liver 

















NLR (lower than 
median) 
< 0.001 3.003 (1.896-4.755) 14 
Leucocytes (lower 
than median) 








0.006 0.462–0.881 27 
Arming  (treatment 








NAb (no NAbs 
against 
adenovirus) 
0.033 0.689 (0.490–0.970) 14 
HR hazard ration, CI confidence interval, RR imaging response rate, NLR Neutrophil-to-lymphocyte ratio, Il-8 Interleukin 8, 
HMGB1 High mobility group box 1, GM-CSF Granulocyte-macrophage colony-stimulating factor, NAb neutralizing antibody 
1) Significance was found only in RR, however we decided to combine the metastasis data in the oncograms as suggestive 
trends were also seen in OS and presence on peritoneal metastasis seemed to suggest good RR and OS after virus treatments    
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